WHO's in Second to Fifth? Distinguishing PAH from Other Types of PH

AMA/ANCC/ACPE Activity
Talking PAH is a webcast series that highlights the very latest clinical data in pulmonary arterial hypertension. Slides are developed and presented by leading PAH expert physicians and further reviewed and approved by the planning committee.
Pulmonary Hypertension (PH) is currently divided into World Health Organization (WHO) groups based on the perceived etiology of the vascular insult: PAH (Group 1), PH due to left heart disease (Group 2), PH due to lung disease and/or hypoxia (Group 3), PH due to pulmonary artery obstructions (Group 4), and PH due to unclear and/or multifactorial mechanisms (Group 5). Accordingly, therapeutic interventions to address PH differ significantly between groups. However, this classification is less than perfect as there is not only considerable heterogeneity within each group but also overlap between groups. Emerging evidence on phenotyping PH may assist to address these limitations. This on-demand video presentation presents the latest research in diagnosing and managing Groups 2-5 in patients, including a discussion of the distinctions in specific groups - CTEPH, PH-ILD, PH-COPD.
FACULTY
Steven Nathan, MD
Medical Director, Advanced Lung Disease and Transplant Program
Inova Fairfax Hospital
Anjali Vaidya, MD, FACC, FASE, FACP
Co-Director, Pulmonary Hypertension, Right Heart Failure, CTEPH Program
Director, Pulmonary Hypertension Fellowship
Temple University
Review the activity at bit.ly/3BB0k0d and claim AMA, ANCC or ACPE credit/contact hour after completion of a brief pretest and posttest/evaluation.
This activity is jointly provided by the University of Nebraska Medical Center, Duquesne University School of Pharmacy and Practice Point Communications
Supported by independent educational grants from United Therapeutics, Bayer U.S. and Actelion Pharmaceuticals U.S., Inc., A Janssen Pharmaceutical Company of Johnson & Johnson
#freecme #PAH #practicepointcme